Washington Hospital brings awareness to heart disease prevention – msnNOW

Click to expand

UP NEXT

Washington Hospital Healthcare System makes it their mission to provide advanced medical services, research, and education to improve and maintain the health status of their patients.

Washington Hospital continues to deliver numerous specialized programs and clinical services including neuroscience, orthopedics, cancer care, and much more. In this episode, learn the warning signs for heart disease, as well as prevention.

Located in Fremont, California, Washington Hospital has delivered leading healthcare services to patients since 1958.

The health professionals at Washington Hospital are dedicated to the patient-first ethic by offering the highest quality care to individuals in need of medical attention.

Address:

Washington Hospital Healthcare System

2000 Mowry Ave

Fremont, CA 94538

See Washington Hospital Healthcare System's website here.

View original post here:
Washington Hospital brings awareness to heart disease prevention - msnNOW

Neuroscience Market Feasibility Current and Future Growth and Regional Analysis and future forecast 2026 – Redhill Local Councillors

The Neuroscience Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Neuroscience Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Neuroscience Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2487

Geographical segmentation of Neuroscience Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Neuroscience Market: Competitive Landscape

Leading players operating in the global market include: Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Blackrock Microsystems LLC, Femtonics Ltd., Intan Technologies, LaVision Biotec GmbH, Mediso Medical Imaging Systems, Neuralynx Inc., NeuroNexus Technologies, Inc., Newport Corporation, Plexon Inc., Noldus Information Technology, Scientifica Ltd., Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

Scope of the Report

The key features of the Neuroscience Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Neuroscience Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2487

Important Neuroscience Market Data Available In This Report:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports Visit This Blog: http://bit.ly/Rajkumar123

View post:
Neuroscience Market Feasibility Current and Future Growth and Regional Analysis and future forecast 2026 - Redhill Local Councillors

Neuroscience Antibodies and Assays Market to Register a Healthy CAGR Throughout 2017 – TechNews.mobi

Global Neuroscience Antibodies and Assays Market Report Market Size, Share, Price, Trends and Forecast is a professional and in-depth study on the current state of the global Neuroscience Antibodies and Assays industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. The compilation also covers information about clients from different industries, which is very important for the manufacturers.

There are 4 key segments covered in this Neuroscience Antibodies and Assays market report: competitor segment, product type segment, end use/application segment, and geography segment.

Request Sample Report @ https://www.marketresearchreports.biz/sample/sample/6904?source=atm

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India Companies

The information for each competitor includes:

* Company Profile

* Main Business Information

* SWOT Analysis

* Sales, Revenue, Price, and Gross Margin

* Market Share

Send Enquiry On This Report @ https://www.marketresearchreports.biz/sample/enquiry/264?source=atm

key players strategies

The main aim of the report is to:

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Important key questions answered in Neuroscience Antibodies and Assays market report:

What will the market growth rate, overview, and analysis by type of global Neuroscience Antibodies and Assays in 2029?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Neuroscience Antibodies and Assays market?

What is dynamics, this overview includes analysis of scope and price analysis of top manufacturers profiles?

What are the opportunities, risks, and the driving forces behind of Neuroscience Antibodies and Assays market? What are the major upstream raw materials sourcing and downstream buyers?

What is the business overview by type, applications, gross margin, and market shares?

What are the opportunities and threats faced by manufacturers in the global Neuroscience Antibodies and Assays market?

Check Discount On This Report @ https://www.marketresearchreports.biz/sample/checkdiscount/6904?source=atm

Tags: China Neuroscience Antibodies and Assays Market TrendEurope Neuroscience Antibodies and Assays Market GrowthUK Neuroscience Antibodies and Assays MarketUS Neuroscience Antibodies and Assays

Read more:
Neuroscience Antibodies and Assays Market to Register a Healthy CAGR Throughout 2017 - TechNews.mobi

Hoberock Appointed to Mizzou Board of Curators | Washington – The Missourian

Missouri Gov. Mike Parson, Wednesday, appointed Gregory Hoberock, Washington, to the University of Missouri Board of Curators.

Hoberock is CEO and chairman of the board of hth companies, inc. He has been with hth since 1984, previously holding the roles of general manager and president.

Hoberock is a member of Associated Builders and Contractors, serving as President of the Construction Legal Rights Foundation.

He has served as a member of the State Technical College of Missouri Board of Regents since 2018.

He is also a member of Associated General Contractors, the Washington Town & Country Fair Board, and the Washington School District WINGS Foundation Board. Mr. Hoberock holds a Bachelor of Science in biochemistry from the University of Missouri-Columbia.

Read this article:
Hoberock Appointed to Mizzou Board of Curators | Washington - The Missourian

Global Itaconic Acid Market 2019 Scope of Current and Future Industry 2024 – Chronicle 99

The research report GlobalItaconic Acid Market Growth 2019-2024presents a unique tool for analyzing the market in terms of strengths and weakness, highlighting opportunities, and supporting strategic and skillful decision-making. The report discovers the newest industry data about the long-run prospects of this Itaconic Acid market, which can help industry contenders to understand the market flow throughout the period 2019-2024.

The report describes the market in detail in terms of the economic and regulatory factors that are currently shaping themarkets growth trajectory, the regional segmentation of the global market, and an analysis of the markets downstream and upstream value andsupply chains. Further, the industry structure together with the landscape, the problems along with business strategies and market effectiveness are covered in this report.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/212512/request-sample

Key Findings By This Report:

The report also presents the market competitive landscape and a corresponding detailed analysis of the major vendor/manufacturers in the Itaconic Acid market. The reportprovides knowledge of the leading market players within the market. The key manufacturers covered in this report:Kehai Biochemistry, Guoguang Biochemistry, Alpha Chemika, Zhongshun Science & Technology, Huaming Biochemistry,

The report includes market division study over the significant geographies of the world such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

Moreover, in this report, other aspects such as customer base, sales reach, local coverage, production price trends, and production cost layout are also analyzed. Profiles of competitors of the Itaconic Acid market as well as core competencies and investments in each segment and an innovative analysis of their current developments has been provided in this research study. The market reports provide all data with easily digestible information to guide every businessmans future innovation and move the business forward.

The Goals of This Report:

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-itaconic-acid-market-growth-2019-2024-212512.html

Moreover, the report packs product analysis, mergers, collaborations, and supply chains analysis. The research report offers market dimensions and evaluations for the period from 2019 to 2024. The complete value chain, as well as downstream and upstream essentials, are further investigated in this report. The market values presented in this report is based on data and information collected at a regional stage.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See the original post:
Global Itaconic Acid Market 2019 Scope of Current and Future Industry 2024 - Chronicle 99

86-year-old Copaxone creator has no intention of slowing down – The Jerusalem Post

For 86-year-old Prof. Ruth Arnon, nothing compares to waking up in the morning and going to work in the laboratory.When it comes to being excited by experiments, age is simply not a factor for the world-renowned Weizmann Institute of Science biochemist and co-creator of multiple sclerosis drug Copaxone.Born in Tel Aviv in 1933, Arnons academic background was in biochemistry, but she worked her entire career to advance a chemical approach to immunology.She currently heads the scientific advisory board of BiondVax Pharmaceuticals, a Jerusalem-based company developing an unprecedented, universal influenza vaccine based on decades of her research at the Weizmann Institute. In 2010, Arnon become the first female president of the Israel Academy of Sciences and the Humanities.There is nothing more exciting than planning an experiment and getting the results, Arnon told The Jerusalem Post. If you get the results you wanted, its extremely exciting. If you didnt expect the results, it can sometimes be even more exciting.Israeli pharmaceutical giant Teva received FDA approval for Copaxone in 1996, a prime example of unexpected but greatly exciting results. The drug is indicated for reducing the frequency of relapses among multiple sclerosis.Already in my PhD, I studied synthetic polymers in order to look at their universal properties and to see whether there is a correlation between the structure of the protein-like polymers and immunological properties, Arnon said.Her studies subsequently led to the development of a synthetic polymer of amino acids, similar to a protein involved in multiple sclerosis. Arnon and her co-researchers originally intended to develop a polymer to mimic the disease in animals, but they found the polymer did not induce a disease. On the contrary, it inhibited the disease.With these results, we made a switch in our minds and studied the properties of this polymer as an inhibitor, she said. Eventually, it led to Copaxone.Today, BiondVax is building on Arnons immunology research and making encouraging strides toward developing a universal, multi-season and multi-strain flu vaccine that has eluded researchers for decades. Approval of the vaccine will represent a major transformation in the field of influenza immunology, which currently operates according to instructions issued by the World Health Organization (WHO).The company is now in the final stage of human clinical trials, with studies to date showing the vaccine to be safe, well-tolerated and immunogenic to a broad range of influenza strains. Results are expected at the end of the current flu season.We looked at the structure of several proteins of influenza, and we focused on regions in the proteins that do not change, Arnon said. Assuming that we immunize with a synthetic molecule containing the regions conserved among many strains of influenza, then this material will be able to provide immunity against many strains of the virus.Recognizing her distinguished career and contributions to medical research, Arnon was awarded the 2020 OurCrowd Maimonides Award for Lifetime Achievement in Science, Leadership and Menschlichkeit at the OurCrowd Global Investor Summit on Thursday. She was welcomed with a standing ovation by thousands of attendees.Presenting the award, OurCrowd founder and CEO Jon Medved paid tribute to Arnon, saying: Countless people owe her their lives and their quality of life to her hard work and innovation.In addition to roles at the Weizmann Institute and the Israel Academy, Arnon has served in many senior national and international positions, including president of the European Federation of Immunological Societies, secretary-general of the International Union of Immunological Societies and on the steering committee of the WHO Task Force on Immunological Methods for Fertility Control.Regarding aspiring scientists, Arnon told the Post her most important advice was to do what you love most and work on that.Whatever you love, you will do with excitement, and it will give you pleasure. Dont try to force yourself to do things that you dont like, she said. I think scientists are fortunate in the sense that they can really follow their philosophy and do what they love most.

Link:
86-year-old Copaxone creator has no intention of slowing down - The Jerusalem Post

Use and utility of serologic tests for rheumatoid arthritis in primary care. – Physician’s Weekly

In this retrospective, register-based population study, we evaluated if anti-citrullinated protein antibodies (ACPA) is a better choice than immunoglobulin M rheumatoid factor (IgM RF) in primary care when rheumatoid arthritis (RA) is suspected, as it determines predictive values in real-life settings. Furthermore, the study described ordering patterns to investigate the benefit of repeated testing.Test result, requisitioning unit, test date and the patients social security number were collected from the Department of Clinical Immunology at Odense University Hospital in 2007-2016 and merged with patient diagnoses from the Danish National Patient Registry.Overall, 5% were diagnosed with RA. IgM RF remained the preferred test during the entire period. Test sensitivity was 61% for IgM RF and 54% for ACPA. The test specificity was 88% for IgM RF and 96% for ACPA. Positive predictive value (PPV) was higher for ACPA than for IgM RF (30% versus 12%) and negative predictive value (NPV) was equal (99%) in primary care. Few individuals seroconverted from negative to positive (ACPA 2% and IgM RF 5%) and positive to negative (ACPA 3% and IgM RF 6%).ACPA has a higher PPV for RA than IgM RF, whereas their NPV is identical. ACPA is the better choice when testing for RA in primary care. Seroconversion is rare, and it is only rarely relevant to retest.The Department of Clinical immunology at Odense University Hospital funded the study.not relevant.Articles published in the DMJ are open access. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

See the article here:
Use and utility of serologic tests for rheumatoid arthritis in primary care. - Physician's Weekly

Chaplin elected as a distinguished fellow of the American Association of Immunologists – UAB News

Chaplin has been chosen as a distinguished fellow by the American Association of Immunologists for his contributions to the field of immunology.

David Chaplin, M.D., Ph.D.David Chaplin, M.D., Ph.D., professor in the Department of Microbiology at the University of Alabama at Birmingham, has been elected as a distinguished fellow by the American Association of Immunologists.

This is a very important and prestigious professional award from the AAI, said Frances Lund, Ph.D., chair of the UAB microbiology department. Its designed to recognize scientists who have spent their career working to advance the field of immunology through their research, their service to the larger national research community, and their contributions to educating and mentoring the next generations of immunologists.

Chaplin has had a significant impact on the education, mentoring and training of immunologists at UAB. He served for more than a decade as chair of the Department of Microbiology and mentored numerous junior faculty who have gone on to become successful academic scientists. After stepping down as chair, Chaplin worked with the Center for Clinical and Translational Science and the School of Medicine Deans Office to organize training academies and workshops for faculty in the early stages of their careers.

The American Association of Immunologists has provided a wonderful professional home for me throughout my career and has offered a way for me to expand my relationships with other immunologists in the field as I serve the scientific community, Chaplin said. Its also been a terrific venue to develop interests outside of my lab, especially through the Committee on Public Affairs. Im deeply humbled and honored to have been designated as an AAI distinguished fellow.

Over his time at UAB, Chaplin and his lab have made key discoveries about the development, structure and function of lymphoid tissues. Additionally, other research he has done has been critical for identifying proteins in the immune system that are now being targeted with immunotherapies. If successful, this method can be used to treat chronic inflammatory diseases like rheumatoid arthritis and asthma.

Aside from his role as an educator and in addition to being a distinguished fellow of AAI, Chaplin is a member of the American Academy of Allergy, Asthma and Immunology, the American Association for the Advancement of Science, and the American Society for Microbiology, and holds memberships within six other organizations that are determined to make a difference within the field of microbiology and immunology.

This is the second year that the AAI has elected distinguished fellows. In the inaugural year, Judith Kapp, Ph.D., and Robert Rich, M.D., were the first two from UAB to receive this honor. Rich is a professor of medicine and formerly served as dean of the UAB School of Medicine, and Kapp is professor emeritus in the UAB Department of Ophthalmology and Visual Sciences.

At UAB, Lund holds the Charles H. McCauley Chair of Microbiology.

Excerpt from:
Chaplin elected as a distinguished fellow of the American Association of Immunologists - UAB News

Air pollution may aggravate nasal suffering with colds and seasonal allergies – WHTC News

Thursday, February 13, 2020 3:39 p.m. EST

By Lisa Rapaport

(Reuters Health) - People who get rhinitis - an inflamed or congested nose - from colds or allergies may feel much worse if they're exposed to high levels of air pollution, a recent study suggests.

Rhinitis usually involves some combination of congestion, sneezing, nasal irritation and sometimes a reduced sense of smell, and it affects up to half of the world's population, the study team writes in Journal of Allergy & Clinical Immunology.

"Breathing polluted air will cause inflammation and oxidative stress on the respiratory tract," said lead study author Emilie Burte of INSERM in Villejuif, France.

"That probably will increase the frequency or severity of rhinitis symptoms," Burte said by email.

Even though rhinitis is especially common among people with asthma - a condition that's aggravated by air pollution - research to date hasn't offered a clear picture of how air quality impacts the severity of rhinitis.

For the current study, researchers examined data on air pollution exposure and symptom severity for about 1,400 people with rhinitis in 17 European cities.

Two types of pollutants in particular were associated with worse rhinitis symptoms: nitrogen oxide, a byproduct of fossil fuel combustion that contributes to smog; and so-called PM 2.5, a mixture of solid particles and liquid droplets smaller than 2.5 micrometers in diameter that can include dust, dirt, soot and smoke.

People in cities with the highest levels of PM 2.5, or fine particulate matter, reported the most severe rhinitis symptoms.

Each increase of 5 micrograms per cubic meter of air (mcg/m3) in concentrations of fine particulate matter was associated with a 17% higher chance that people with rhinitis would experience severe symptoms, the study found.

Fine particulate matter was associated with worse congestion, nasal irritation and sneezing.

Nitrogen dioxide was also tied to more severe rhinitis, particularly for symptoms like nasal discharge and congestion.

The pollutants exacerbating rhinitis in the study have long been linked to traffic fumes, with worse air quality around major roadways in cities around the world.

While the study wasn't designed to prove whether air pollution causes rhinitis or makes symptoms worse, it's possible that each kind of contaminant in the air does its own type of damage in the respiratory system, Burte said.

People prone to colds and allergies can't do much to prevent pollution from making rhinitis worse, aside from staying indoors, said Yaguang Wei, an environmental health researcher at Harvard University in Boston who wasn't involved in the study.

People can pay attention to air quality alerts for their city or community and plan to stay indoors or at least avoid vigorous activity outside during peak pollution times.

"For indoor air pollution, air purifiers can clean indoor air and protect your family, especially for children and the elderly," Wei said by email.

People can also do their part to reduce traffic fumes.

"Using public transportation can help reduce air pollution emissions," Wei said.

SOURCE: https://bit.ly/31W84az Journal of Allergy & Clinical Immunology, online January 23, 2020.

Read more from the original source:
Air pollution may aggravate nasal suffering with colds and seasonal allergies - WHTC News

Understanding how a protein wreaks havoc in the brain in Parkinson’s disease – Engineers Journal

What causes neurons to die in Parkinsons disease?

What causes neurons to die in Parkinsons disease?

Parkinsons disease is a long-term (chronic) neurological condition that affects about 12,000 people in Ireland and between seven and 10 million people worldwide.

The disease affects the way the brain co-ordinates body movements like walking and talking, but cognitive abilities are also affected.

There is currently no cure for the disease, but researchers at Trinity have recently published findings of a study which may lead to better treatments for this debilitating illness. The paper has been published in the international Cell Press journal Structure.

Neurons in the part of the brain called substantia nigra (dark matter) produce and release a hormone called dopamine. This hormone acts as a messenger between these cells in the substantia nigra and other parts of the brain which control body movements.

If these specialised neurons become damaged or die, the amount of dopamine in the brain is reduced. This means that the parts of the brain that control movement cease to function normally, said Amir Khan, associate professor, School of Biochemistry and Immunology at Trinity.

The only treatment for Parkinsons disease in the last 20 years has been dopamine replacement therapy. This involves providing a substitute to try to increase the levels of the hormone in the brain. However, the treatment is not completely effective and can wear off over time, and it also has side effects.

The main reason why we lack new treatments is that we dont understand the fundamental mechanism of how neurons become sick and die. No one knows why these particular neurons in the substantia nigra are affected.

In the last few years, the field has completely changed. We have new insight into a gene called LRRK2, which is the most common cause of inherited Parkinsons disease. Although only 10% of Parkinsons cases are inherited, the enzyme that is produced by the LRRK2 gene seems to be overactive in both inherited and sporadic cases.

In other words, afflicted individuals may not have an LRRK2 mutation, but the enzyme runs amok in their neurons anyway. Inhibitors of this enzyme are now in late clinical trials for treatment of Parkinsons disease.

The team at Trinity has studied the effects that LRRK2 has on other proteins in neuronal cells. To understand how LRRK2 affects the brain and leads to Parkinsons disease, the team has simulated the activity of the enzyme in the laboratory.

The research allowed us to visualize the 3D structure of a protein complex that is formed when LRRK2 is overactive. From these structural studies of proteins, we can understand how LRRK2 is able to impose its profound effects on neurons. We are the first group to report the effects of LRRK2 in 3-D detail using a method called X-ray crystallography, said Prof Khan.

An overactive LRRK2 runs loose in neurons and wreaks havoc on motor and cognitive abilities. In a way, we are chasing the footprints that LRRK2 leaves in the brain to understand what it does, and find ways to stop it.

We are hopeful that these studies may eventually lead to new treatments for Parkinsons disease, for which there is currently no cure.

What causes neurons to die in Parkinsons disease?Parkinsons disease is a long-term (chronic) neurological condition that affects about 12,000 people in Ireland and between seven and 10 million people worldwide.Cognitive abilities affectedThe disease affects the way the brain co-ordinates body movements like walking and talking, but cognitive abilities are...

More:
Understanding how a protein wreaks havoc in the brain in Parkinson's disease - Engineers Journal